High-risk myeloma: a challenge to define and to determine the optimal treatment

Lancet Haematol. 2021 Jan;8(1):e4-e6. doi: 10.1016/S2352-3026(20)30361-6. Epub 2020 Dec 22.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Bortezomib
  • Dexamethasone
  • Humans
  • Lenalidomide
  • Multiple Myeloma* / diagnosis
  • Multiple Myeloma* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • elotuzumab
  • Bortezomib
  • Dexamethasone
  • Lenalidomide

Associated data

  • ClinicalTrials.gov/NCT00869232
  • ClinicalTrials.gov/NCT02128230
  • ClinicalTrials.gov/NCT03004287
  • ClinicalTrials.gov/NCT03188172
  • ClinicalTrials.gov/NCT03606577
  • ClinicalTrials.gov/NCT03104842
  • ClinicalTrials.gov/NCT00081939
  • ClinicalTrials.gov/NCT00572169